Aurobindo Pharma’s subsidiary Eugia secures FDA nod for pazopanib tablets

Aurobindo Pharma Limited, through its wholly owned subsidiary Eugia Pharma Specialities Limited, has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Pazopanib Tablets, 200 mg. This critical approval allows Eugia Pharma to launch a generic equivalent of Votrient Tablets, 200 mg, developed by Novartis Pharmaceuticals Corporation. The company anticipates introducing this product in the final quarter of the 2025 fiscal year, aiming to tap into a lucrative market estimated at $106 million as of October 2024, according to IQVIA.

Pazopanib Tablets, 200 mg, cater to a vital therapeutic need, being indicated for adults with Advanced Renal Cell Carcinoma (RCC) and Advanced Soft Tissue Sarcoma (STS) who have undergone prior chemotherapy. This marks a significant milestone for Eugia Pharma, adding to its extensive portfolio of 179 ANDA (Abbreviated New Drug Application) approvals, which include both oral and sterile oncology specialties. The company’s achievements underscore its growing prominence in the competitive global pharmaceutical landscape.

Industry analysts highlight the importance of this development in strengthening Aurobindo Pharma’s oncology portfolio, which is a strategic focus area. Pazopanib, with its bioequivalent properties, offers a cost-effective alternative to Votrient, enhancing accessibility for patients requiring long-term treatment. The regulatory approval also reaffirms the company’s commitment to maintaining stringent manufacturing standards across its facilities, accredited by global regulatory bodies such as USFDA, UK MHRA, and Japan PMDA.

Experts note that Aurobindo Pharma’s robust infrastructure, comprising 29 manufacturing units approved by leading regulatory agencies, plays a pivotal role in ensuring consistent quality and supply. With a diversified product portfolio spanning CNS, cardiovascular, and anti-infectives, among others, the company is well-positioned to consolidate its market share in the oncology segment.

Eugia Pharma’s move to enter the Pazopanib market aligns with the growing demand for effective cancer therapies. Market observers anticipate that the product launch will provide a significant boost to the company’s revenue trajectory, leveraging the sizeable market potential.

Aurobindo Pharma’s emphasis on innovation and patient-centric solutions continues to drive its strategic initiatives, as evidenced by this latest USFDA approval. The company remains committed to expanding its footprint in over 150 countries, delivering affordable and high-quality pharmaceutical products.